Stada already had two interested buyers in the mix as of earlier this week. And now, it’s got three.
The German drugmaker confirmed Thursday afternoon that it had received yet another expression of buyout interest, this one from a mystery buyer indicating it was willing to fork over €58 ($68.60) per Stada share. That’s an increase on the €56 ($59.48) per share—or €3.5 billion ($3.72 billion)—floated by private equity suitor Cinven.
“Stada is still weighing up its options on how to react in the best interest of the company,” it said in a statement.
The news follows a pair of announcements from Stada from earlier this week detailing interest from Cinven and fellow private equity outfit Advent International.
Each of the two “could offer in different ways attractive opportunities in the interest of the company,” Stada said in a statement, noting that it was striking up “open-minded talks” that would “allow the interested parties to explain their strategic concepts and evaluate further value-enhancing potential with regards to the potential offer price.”
Still, Stada said Thursday it’s too early to tell whether one or more of the potential bidders will actually offer up a formal proposal.
If they do, it’s likely to make at least one outspoken shareholder happy. Last summer, when Stada was fighting proxy brawler Active Ownership Capital, U.S.-based rebel investor Guy Wyser-Pratte made it clear that he’d prefer a sale instead of a board revamp. “Why wait five years instead of selling in five months?” he asked Reuters at the time.
Meanwhile, Stada’s used to the flurry of takeover interest after a busy 2016. Last year, the company and private equity firm CVC Capital Partners reportedly held informal talks on a deal worth up to €3.7 billion, and other private equity outfits got in touch with Stada around the same time, too.
By Carly Helfand
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.